Controlling Polymorphic Impurities in Pharmaceutical Processes

  • Crystallization
  • 12 May 2026

About the webinar

In this webinar, guest speaker Jude Eames from Eurofins CDMO Alphora shares a case study on polymorphic impurities in pharmaceutical process development.

The case study highlights the importance of understanding polymorphic transitions to isolate a less thermodynamically stable polymorph. It highlights how the Crystal16 and Crystalline were utilized to diagnose problems in the process.

Polymorphic impurities can be especially problematic: often undetectable in early stages. They may only surface later in development. This leads to process redesign and costly delays.

Guest speaker

Jude Eames

Team Leader Solid-State Group at Eurofins CDMO Alphora

As a Team Leader in the Solid-State group at Eurofins CDMO Alphora, I have had the privilege of collaborating with a diverse range of clients and projects. I have over a decade of experience in characterizing materials and more than five years in pharmaceutical research. My focus is on ensuring robust processes that consistently deliver high-quality materials, overcoming unique challenges with innovative solutions. Outside of work, I enjoy spending time with my cat and playing Aussie Rules Football.

Watch webinar recording